NASDAQ:ACON Aclarion (ACON) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free ACON Stock Alerts $0.30 +0.01 (+1.81%) (As of 12:15 PM ET) Add Compare Share Share Today's Range$0.29▼$0.3050-Day Range$0.28▼$1.2252-Week Range$0.27▼$25.60Volume194,429 shsAverage Volume2.94 million shsMarket Capitalization$2.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Aclarion alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Aclarion Stock (NASDAQ:ACON)Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.Read More ACON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACON Stock News HeadlinesApril 25, 2024 | globenewswire.comAclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back PainApril 23, 2024 | finance.yahoo.comAclarion to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024May 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.April 2, 2024 | benzinga.comWhy Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 4, 2024 | finance.yahoo.comAclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar DiscsFebruary 27, 2024 | globenewswire.comAclarion Announces Closing of $3.0 Million Public OfferingFebruary 26, 2024 | msn.comWhy Aclarion (ACON) Shares Are Down Over 60% TodayFebruary 26, 2024 | globenewswire.comAclarion Announces Pricing of $3.0 Million Public OfferingMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.February 26, 2024 | investorplace.comWhy Is Aclarion (ACON) Stock Down 19% Today?February 26, 2024 | investorplace.comWhy Is Aclarion (ACON) Stock Down 19% Today?February 1, 2024 | benzinga.comAclarion Stock (NASDAQ:ACON), Short Interest ReportJanuary 30, 2024 | benzinga.comAclarion Stock (NASDAQ:ACON) Dividends: History, Yield and DatesJanuary 22, 2024 | markets.businessinsider.comEQS-News: Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MDJanuary 22, 2024 | markets.businessinsider.comAclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MDJanuary 3, 2024 | ca.finance.yahoo.comACLARION INC. DL-,00001 (IT2.BE)January 2, 2024 | finance.yahoo.comAclarion Announces Reverse Stock SplitNovember 27, 2023 | finance.yahoo.comAclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan ExamsNovember 9, 2023 | finance.yahoo.comAclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan AdoptionNovember 6, 2023 | markets.businessinsider.comAclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MDOctober 25, 2023 | finance.yahoo.comAclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to DenverOctober 24, 2023 | finance.yahoo.comAclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM MeetingOctober 2, 2023 | finance.yahoo.comAclarion Provides Updated Investor Presentation and Corporate UpdateSeptember 8, 2023 | barrons.comAclarion Inc.August 25, 2023 | finance.yahoo.comAclarion, Inc. Announces Filing of Delayed 10-Q Quarterly ReportJune 14, 2023 | finance.yahoo.comAclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MIJune 8, 2023 | benzinga.comWhy Aclarion Stock Is Popping TodaySee More Headlines Receive ACON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:ACON CUSIPN/A CIK1635077 Webwww.aclarion.com Phone833-275-2266FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,910,000.00 Net Margins-6,480.47% Pretax Margin-6,512.92% Return on Equity-724.93% Return on Assets-249.67% Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual Sales$80,000.00 Price / Sales26.24 Cash FlowN/A Price / Cash FlowN/A Book Value($0.38) per share Price / Book-0.77Miscellaneous Outstanding Shares7,150,000Free Float5,559,000Market Cap$2.10 million OptionableNot Optionable Beta0.39 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Jeffrey John Thramann M.D. (Age 59)Executive Chairman Comp: $300kMr. John Lorbiecki (Age 60)Chief Financial Officer Comp: $225kMr. Ryan Bond (Age 51)Chief Strategy Officer Comp: $200kMr. Brent Ness (Age 57)CEO, President & Director Comp: $418.75kKey CompetitorsOpGenNASDAQ:OPGNDermata TherapeuticsNASDAQ:DRMAReShape LifesciencesNASDAQ:RSLSNanoVibronixNASDAQ:NAOVCNS PharmaceuticalsNASDAQ:CNSPView All Competitors ACON Stock Analysis - Frequently Asked Questions How have ACON shares performed in 2024? Aclarion's stock was trading at $3.20 at the beginning of the year. Since then, ACON shares have decreased by 90.8% and is now trading at $0.2936. View the best growth stocks for 2024 here. Are investors shorting Aclarion? Aclarion saw a increase in short interest in March. As of March 31st, there was short interest totaling 62,000 shares, an increase of 9.3% from the March 15th total of 56,700 shares. Based on an average trading volume of 1,890,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.0% of the shares of the stock are sold short. View Aclarion's Short Interest. When is Aclarion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our ACON earnings forecast. When did Aclarion's stock split? Shares of Aclarion reverse split before market open on Thursday, January 4th 2024. The 1-16 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Aclarion IPO? Aclarion (ACON) raised $12 million in an initial public offering on Friday, April 22nd 2022. The company issued 2,165,000 shares at $4.50-$6.50 per share. How do I buy shares of Aclarion? Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACON) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsYour bank is lying to you.MyBankTracker Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
